| 
Onno van de Stolpe - Chief Executive Officer
Mr. Van de Stolpe founded Galapagos in 1999 while he was Managing
Director Genomics at Introgene (now Crucell). Prior to joining Introgene
in 1998, he was Managing Director of Molecular Probes Europe. He
established this European headquarters after joining Molecular Probes
in the US. Previously, he worked for the Netherlands Foreign Investment
Agency in California, where he was responsible for recruiting biotech
and medical device companies to locate in the Netherlands. Mr. Van
de Stolpe started his career as Manager Business Development at
MOGEN in Leiden. He received a MSc degree from the Agricultural
University in Wageningen.
Graham
Dixon, PhD - Senior Vice President Drug Discovery
Dr. Dixon joined Galapagos in 2004. Prior to Galapagos, Dr. Dixon
was CSO of Entomed in France. From 2002 to 2003, he was CSO at F2G
in the UK. From 1994-2002, Dr. Dixon had various research &
development management positions at Zeneca and AstraZeneca. He started
his professional career with Dow and later DowElanco. He has a PhD
in Biochemistry from the University of Swansea in the UK.
Andre
Hoekema, PhD - Senior Vice President Corporate Development
Dr. Hoekema joined Galapagos in March 2005 from Invitrogen Corporation,
where he was Managing Director of Corporate Development Europe.
He brings 20 years of biotech experience from positions at Molecular
Probes Europe (Managing Director), Crucell (Director of Business
Development), DSM Life Sciences and MOGEN (Research and Project
Management) and Genentech, Inc (R&D). Dr. Hoekema has a PhD
degree from Leiden University and is the inventor of over 20 series
of patent applications, resulting in 15 patents issued in the US.
Richard
Neale - Senior Vice President North America
Mr. Neale joined Galapagos in October 2006 from Discovery Partners
International where he was member of the Executive Management Team
and held various positions involving strategic, commercial, corporate
and operational aspects of the Company. Prior to DPI, he was Vice
President, Business at Systems Integrated Drug Discovery Company
and Vice President, Business Affairs and General Legal Counsel at
Novopharm Biotech (now Viventia Biotech). Mr. Neale practiced law
in the Corporate/Securities group of Davies Ward & Beck (now
Davies Ward Phillips & Vineberg). He holds a Bachelor of Science
degree from the University of Guelph and Masters of Business Administration
and Law degrees from Dalhousie University.
Chris
Newton, PhD - Senior Vice President BioFocus DPI
Dr. Newton was appointed to BioFocus in 2005. Between 2000 and 2005,
he was a founding scientist and CSO and Board Director at Argenta
Discovery Ltd. From 1979 to 2000, he held a variety of senior management
positions in both research and development in the Rhone-Poulenc
group of companies, working on a variety of projects, some of which
reached clinical trials. Dr. Newton holds a degree in Natural Sciences
from the University of Cambridge and is Emeleus chemistry prize
holder of that university. He earned his PhD at the University of
Sheffield in 1979, for which he was awarded the Turner Prize. Dr.
Newton has been appointed to visiting academic fellowships and professorships
associated with the University of Warwick (1994-1998) and the University
of Essex (1995-1999) during his industrial career.
David
Phillips - Senior Vice President Sales & Marketing
Mr.
Phillips joined BioFocus in 2004 from The Automation Partnership
where he held the position of VP, Sales and Marketing. Prior to
this he has worked for Argenta Discovery Ltd. and has extensive
experience in biotechnology start-up companies. Mr. Phillips graduated
from London University with a degree in Pharmacology and spent 15
years in Sales & Marketing with Glaxo. He has developed global
experience in business development dealing with pharmaceutical companies
in the USA, Europe and Japan.
Dirk
Pollet, PhD - Senior Vice President Licensing & Intellectual
Property
Dr. Pollet joined Galapagos Genomics in September 2000, from Glaxo
Wellcome (Stevenage, UK) where he was Director Molecular Diagnostics
focusing on Pharmacogenetics. Previously, he was Business and Product
Development Manager at Innogenetics NV (Ghent, Belgium) playing
a major role in the development of innovative diagnostics. He received
his PhD degree in Biochemistry from the University of Antwerp.
Leo
Steenbergen – Chief Financial Officer
Mr.
Steenbergen joined Galapagos in June 2007. Prior to Galapagos, he
was CFO and a member of the Management Board of Telenet NV. Under
his management, the company was refinanced and, in 2005, completed
a successful Initial Public Offering on Euronext. Prior to joining
Telenet, Mr. Steenbergen was CEO of IP Globalnet and CFO of the
Bekaert Group. He worked from 1980 to 1997 for Hewlett-Packard Europe
in various finance positions.
Piet
Wigerinck, PhD – Senior Vice President Development
Dr.
Piet Wigerinck joined Galapagos in April 2008 from Tibotec (a subsidiary
of Johnson & Johnson) where he was VP Drug Discovery, Early
Development and CM&C, and a member of the Management Board.
He started his professional career as a medicinal chemist at Janssen
Research Foundation in 1992. He then joined Tibotec in 1998, where,
under his leadership, TMC114 (PrezistaTM) was selected and moved
forward into clinical trials. Dr. Wigerinck also played a key role
in Tibotec’s expansion into novel diseases such as Hepatitis
C and advanced several compounds into Phase I and Phase II clinical
trials. He brings over 15 years of research and development experience
from both big pharma and biotech to Galapagos. Piet Wigerinck holds
a PhD from the K.U. Leuven and is inventor on more than 25 patent
applications.
|
